CurrentBlue Cross Blue Shield - MassachusettsPolicy 177

Low‑dose radiotherapy (LDRT) for non‑oncologic indications

Defines medical necessity and investigational uses of low‑dose radiotherapy for benign conditions (osteoarthritis, plantar fasciitis, keloids, heterotopic ossification) for Blue Cross Blue Shield - Massachusetts members.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyLow‑dose radiotherapy (LDRT) for non‑oncologic indications

Policy CodePolicy 177

Change TypeAnnual reviewliterature update through Sept 12, 2025

Effective DateN/A

Next Review DateN/A

Key ActionObtain precertification when the procedure is performed inpatient; outpatient prior authorization is not required for most commercial and Medicare products.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2investigational

2medically necessary

typical HO doseHO dose

12–20 Gykeloid dose

noneCPT code

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations and Criteria

Indication-specific coverage stance

Coverage stance for named indications

Osteoarthritis: Low-dose radiotherapy is considered INVESTIGATIONAL for the treatment of osteoarthritis.

See evidence summaries summarizing insufficient RCT benefit

Plantar fasciitis: Low-dose radiotherapy is considered INVESTIGATIONAL for the treatment of plantar fasciitis.

Evidence insufficient to determine net health benefit

Heterotopic ossification prophylaxis: Adjuvant low-dose radiotherapy may be considered MEDICALLY NECESSARY for prevention of heterotopic ossification following surgery in individuals determined to be at high risk for development of heterotopic ossification (see Policy Guidelines).

High-risk patient characteristics listed in Policy Guidelines

Keloids (postoperative adjuvant): Adjuvant low-dose radiotherapy may be considered MEDICALLY NECESSARY following surgical excision for the treatment of keloids.

Treatment typically initiated immediately to 48 hours post-surgery with total doses 7-20 Gy; guidance in Policy Guidelines

HO prophylaxis — covered with evidence

Heterotopic ossification (HO) prophylaxis

HO summary conclusion: Comparative studies report LDRT comparable to NSAIDs and superior to historical controls; overall evidence judged sufficient to improve net health outcome.

Based on 2 systematic reviews, multiple RCTs and comparative studies; adverse events similar between groups.

Keloid adjuvant LDRT — covered with evidence

Keloid recurrence prophylaxis

Keloid summary conclusion: Adjuvant low-dose radiotherapy following surgical excision is generally safe and, in most comparative studies, of similar effectiveness to alternative adjunctive therapies; evidence is sufficient to determine an improvement in net health outcome for prevention of keloid recurrence.

Based on 2 systematic reviews, 5 RCTs, and comparative studies; limitations include small sample sizes and short follow-up.

Several other benign dermatologic and soft-tissue disorders are mentioned in the policy as having some published evidence for low-dose radiotherapy (LDRT) but are not specifically addressed within this medical policy. Examples listed include achillodynia, Dupuytren's contracture, medial and lateral epicondylitis, Graves ophthalmopathy, hidradenitis suppurativa, Ledderhose disease, Peyronie's disease, pterygium, tendinopathies, and trochanteric bursitis. The policy states these conditions are excluded from the focused scope because of limited high-quality evidence, variable clinical practice, or available alternative standard treatments, and that use of LDRT for these conditions should be considered on a case-by-case basis.

The excerpt does not list formal or explicit exclusions beyond noting that some other benign conditions are not addressed in this policy. It states that no additional exclusion list is provided in the excerpt and that indications not covered by the policy may be considered individually based on clinical context and evidence availability.

The policy explicitly categorizes the use of LDRT for osteoarthritis and plantar fasciitis as INVESTIGATIONAL. As investigational uses, these indications are considered not medically necessary per the policy due to insufficient evidence demonstrating a net health benefit.

Overall the evidence base across benign indications is mixed. For heterotopic ossification (HO) and keloid prevention, systematic reviews, randomized trials, and comparative studies exist and the policy judges the evidence sufficient to support a net health benefit in those settings. By contrast, for other outcomes and indications the trial results are heterogeneous, sample sizes are small, and follow-up is often short. The document does not present a separate, comprehensive list of conditions deemed "not medically necessary" beyond labeling osteoarthritis and plantar fasciitis investigational; instead it summarizes that evidence is mixed for many non-oncologic uses and reserves decisions for unlisted conditions to case-by-case consideration.

Procedure and Billing Codes

CPT/HCPCSCPT

No codes listed

Provider Responsibilities and Authorization Requirements

Prior Authorization

Inpatient Precertification Required

For services described in this policy, precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient.

Inpatient: precertification/preauthorization required for all products if procedure performed inpatient.

Prior Authorization

Outpatient Prior Authorization

For services described in this policy, prior authorization is not required for outpatient settings across Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM.

Outpatient: Commercial Managed Care (HMO and POS) – Prior authorization not required.
Outpatient: Commercial PPO and Indemnity – Prior authorization not required.
Outpatient: Medicare HMO Blue SM – Prior authorization not required.
Outpatient: Medicare PPO Blue SM – Prior authorization not required.

Key Terms and Definitions

inv-18: Low-dose radiotherapy (LDRT) — definition and typical dosing context

DefinitionRadiation therapy delivered at lower doses than cancer radiotherapy, commonly <1 Gy per fraction with total doses generally below 20 Gy, used for anti-inflammatory and antiproliferative effects in benign conditions.

Typical fractionation examples0.5 Gy twice weekly for 3 weeks or 1.0 Gy once weekly for 6 weeks (multiple low-dose fractions with total dose usually <20 Gy).

Common delivery methodsExternally via photon or heavier particle beams; various ionizing radiation types may be used.

Clinical contextExplored for noncancerous inflammatory and degenerative musculoskeletal and soft-tissue diseases after conventional treatments fail.

Policy-relevant thresholdsTotal doses generally below 20 Gy for benign indications per policy background.

Clinical and Evidence Background

Low-dose radiotherapy (LDRT) refers to radiation therapy delivered at doses lower than those used for cancer treatment and is thought to exert anti-inflammatory and antiproliferative effects. Typical benign-treatment schedules use multiple low-dose fractions with total doses generally below 20 Gy (and often <1 Gy per fraction), and LDRT has been explored for a range of noncancerous inflammatory and degenerative musculoskeletal and soft-tissue conditions when conventional treatments have failed.